Regulus Therapeutics Inc (RGLS)
2.27
+0.05
(+2.25%)
USD |
NASDAQ |
Apr 25, 16:00
2.29
+0.02
(+0.88%)
After-Hours: 20:00
Regulus Therapeutics Net Income (TTM): -30.04M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -30.04M |
| September 30, 2023 | -28.77M |
| June 30, 2023 | -28.50M |
| March 31, 2023 | -28.74M |
| December 31, 2022 | -28.32M |
| September 30, 2022 | -28.66M |
| June 30, 2022 | -29.74M |
| March 31, 2022 | -28.51M |
| December 31, 2021 | -27.81M |
| September 30, 2021 | -22.00M |
| June 30, 2021 | -14.89M |
| March 31, 2021 | -15.81M |
| December 31, 2020 | -15.73M |
| September 30, 2020 | -19.30M |
| June 30, 2020 | -23.20M |
| March 31, 2020 | -21.27M |
| December 31, 2019 | -18.59M |
| September 30, 2019 | -22.26M |
| June 30, 2019 | -27.11M |
| March 31, 2019 | -35.94M |
| December 31, 2018 | -48.71M |
| September 30, 2018 | -54.59M |
| June 30, 2018 | -60.15M |
| March 31, 2018 | -67.91M |
| Date | Value |
|---|---|
| December 31, 2017 | -71.90M |
| September 30, 2017 | -77.48M |
| June 30, 2017 | -81.17M |
| March 31, 2017 | -80.65M |
| December 31, 2016 | -81.84M |
| September 30, 2016 | -69.04M |
| June 30, 2016 | -62.52M |
| March 31, 2016 | -62.47M |
| December 31, 2015 | -55.75M |
| September 30, 2015 | -70.69M |
| June 30, 2015 | -67.49M |
| March 31, 2015 | -58.43M |
| December 31, 2014 | -56.68M |
| September 30, 2014 | -36.44M |
| June 30, 2014 | -28.80M |
| March 31, 2014 | -24.18M |
| December 31, 2013 | -18.67M |
| September 30, 2013 | -23.62M |
| June 30, 2013 | -27.14M |
| March 31, 2013 | -22.39M |
| December 31, 2012 | -17.41M |
| September 30, 2012 | -12.55M |
| June 30, 2012 | -7.906M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-30.04M
Minimum
Dec 2023
-14.89M
Maximum
Jun 2021
-24.17M
Average
-27.11M
Median
Jun 2019
Net Income (TTM) Benchmarks
| ACADIA Pharmaceuticals Inc | -61.29M |
| ADMA Biologics Inc | -28.24M |
| FibroGen Inc | -284.23M |
| Protara Therapeutics Inc | -40.42M |
| Amylyx Pharmaceuticals Inc | 49.27M |